Cowen analyst Ritu Baral raised the firm’s price target on Sarepta to $125 from $114 and keeps an Outperform rating on the shares. The analyst said they pre-announced 4Q22 PMO revenues of 235.5M and FY22 of 843.3M on organic pt demand in the US. He thinks an AdComm is very likely for SRP-9001, especially if the BLA is potentially approvable although the company has not yet received any such confirmation by the FDA.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SRPT:
- UBS Says These 2 Stocks Offer Attractive Risk-Reward Right Now — Here’s Why
- Sarepta price target raised to $160 from $158 at Needham
- Sarepta price target raised to $114 from $101 at Credit Suisse
- Sarepta expects to exceed FY22 guidance for net product revenues
- Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues